摘要
图 上周五上午听的是Longevity Biotech Fellowship（LBF）的运营负责人Eric Magro的分享。这个成立约三年的非营利组织专注一件事：把“解决衰老”当成一个值得立项、拨款、招人的工程问题来做。 Eric开场放了一张死亡率曲线。年轻时，我们的死亡概率几乎贴地飞行，到了某个年龄后会突然指数级拉升。衰老，是全球大多数人的死因本质，但目前没有一个国家或大型机构在系统性地拆解这个问题。LBF的路线图就是想补上这个“战略空白”。 Last Friday morning I sat in on a session by Eric, Head of Operations from Longevity Biotech Fellowship (LBF). Founded roughly three years ago, this nonprofit focuses on one thing: treating "solving aging" as an engineering problem worthy of formal project launch, funding, and hiring. Eric opened with a mortality curve. When we're young, the probability of death hovers near zero; after a certain age, it spikes exponentially. Aging is essentially the leading cause of death worldwide, yet no country or major institution is systematically dismantling the problem. LBF's roadmap aims to fill this strategic void. [ LBF把解题思路系统性地拆成三条（难度和资金需求依次递减）] 生物工程（Bioengineering）：彻底理解衰老生物学并干预。Eric认为这是最难、最花钱、最遥远的方向，因为人类至今没有公认的衰老理论框架，连因果通路都没完全摸清。